CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with


August 1, 2017 (STL.News) Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been [ ] The post CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with appeared first on STL News.
http://bit.ly/2uftaOI

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s